Bone metastases in appendiceal adenocarcinoma

The prognosis of mucinous appendiceal adenocarcinoma with PSD has changed significantly over the last 20 years with evolving treatment mo- dalities, most notably cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Before CRS/HIPEC, local control with repeated drainage...

Full description

Saved in:
Bibliographic Details
Published in:The American surgeon 2014-09, Vol.80 (9), p.e274-275
Main Authors: Huck, Michael B, Shen, Perry
Format: Article
Language:English
Subjects:
Abdomen
Adenocarcinoma - secondary
Appendiceal Neoplasms - pathology
Appendiceal Neoplasms - therapy
Bone Neoplasms - secondary
Chemotherapy
Fatal Outcome
Female
Humans
Medical imaging
Medical prognosis
Metastasis
Middle Aged
Ovarian cancer
Pathology
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of mucinous appendiceal adenocarcinoma with PSD has changed significantly over the last 20 years with evolving treatment mo- dalities, most notably cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Before CRS/HIPEC, local control with repeated drainage of mucinous ascites and symptomatic debulking yielded 5-year survival rates of six to 50 per cent.2 More recent research has shown a significant increase in sur- vival after CRS/HIPEC with 5-, 10-, and 15-year survival rates of 74, 63, and 59 per cent, respectively.3 Further studies have shown that patients with recurrent PSD from appendiceal cancer who undergo repeat CRS/HIPEC had a median survival of 52 months.4 This treatment modality has significantly changed the survival rate.
ISSN:0003-1348
1555-9823
DOI:10.1177/000313481408000907